Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Status:
Completed
Trial end date:
2016-10-24
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus
dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with
N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma by comparing the
progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine and
by getting a better understanding of the efficacy, safety, pharmacogenomics (PGx) and their
relationship with pimasertib exposure.